Ligand Pharmaceuticals LGND Kyprolis — Total revenue and income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's kyprolis — total revenue and income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's kyprolis — total revenue and income?
- Ligand Pharmaceuticals (LGND) reported kyprolis — total revenue and income of $8.88M in Q4 2025.
- How has Ligand Pharmaceuticals's kyprolis — total revenue and income changed year-over-year?
- Ligand Pharmaceuticals's kyprolis — total revenue and income decreased by 7.4% year-over-year, from $9.59M to $8.88M.
- What is the long-term trend for Ligand Pharmaceuticals's kyprolis — total revenue and income?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's kyprolis — total revenue and income has grown at a 6.6% compound annual growth rate (CAGR), from $27.47M to $35.53M.
- What does kyprolis — total revenue and income mean?
- This metric captures the total royalty-based revenue and related income streams attributable to the Kyprolis product. It reflects the company's ability to monetize its intellectual property and partnership agreements tied to this specific therapeutic asset. This measure is critical for evaluating the profitability and cash flow contribution of the company's royalty-focused business model.